ABBV logo

AbbVie Inc. (ABBV)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

AbbVie Inc. (ABBV) trades at $205.06 with AI Score 52/100 (Hold). AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and selling innovative medicines. Market cap: 363B, Sector: Healthcare.

Last analyzed: Feb 9, 2026
AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and selling innovative medicines. Their diverse portfolio addresses serious health issues across several therapeutic areas, including immunology, oncology, neuroscience, and eye care.
52/100 AI Score Target $254.22 (+24.0%) MCap 363B Vol 3M

AbbVie Inc. (ABBV) Healthcare & Pipeline Overview

CEORobert A. Michael
Employees55000
HeadquartersNorth Chicago, IL, US
IPO Year2013

AbbVie is a global biopharmaceutical leader with a robust portfolio of innovative medicines, including Humira, Skyrizi, and Rinvoq, addressing significant unmet needs in immunology, oncology, and neuroscience, offering investors a compelling blend of stable revenue and growth potential with a solid dividend yield.

Data Provenance | Financial Data Quantitative Analysis NYSE Analysis: Feb 9, 2026

Investment Thesis

AbbVie presents a notable research candidate due to its diversified product portfolio and strong pipeline. While Humira's biosimilar competition poses a challenge, the growth of Skyrizi and Rinvoq is expected to offset revenue declines. The company's focus on innovative therapies in immunology, oncology, and neuroscience positions it for long-term growth. With a market capitalization of $394.89 billion and a dividend yield of 2.98%, AbbVie offers a blend of stability and growth potential. The company's commitment to R&D and strategic acquisitions should drive future value creation. Investors may want to evaluate AbbVie for its potential to generate consistent cash flow and deliver attractive returns.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $394.89 billion, reflecting AbbVie's significant presence in the pharmaceutical industry.
  • P/E ratio of 94.13, indicating investor expectations for future earnings growth.
  • Gross margin of 73.3%, showcasing AbbVie's ability to maintain profitability in its operations.
  • Dividend yield of 2.98%, providing investors with a steady stream of income.
  • Beta of 0.33, suggesting lower volatility compared to the overall market.

Competitors & Peers

Strengths

  • Diversified product portfolio.
  • Strong research and development capabilities.
  • Global sales and marketing network.
  • Established brand reputation.

Weaknesses

  • Reliance on Humira for a significant portion of revenue.
  • Exposure to biosimilar competition.
  • High debt levels.
  • Dependence on regulatory approvals.

Catalysts

  • Upcoming: Clinical trial results for new drug candidates in oncology and neuroscience.
  • Upcoming: Regulatory approvals for new indications of Skyrizi and Rinvoq.
  • Ongoing: Continued growth of Skyrizi and Rinvoq sales.
  • Ongoing: Strategic acquisitions and partnerships to expand the product pipeline.

Risks

  • Ongoing: Biosimilar competition for Humira impacting revenue.
  • Potential: Failure to successfully develop and commercialize new products.
  • Potential: Regulatory setbacks or delays.
  • Potential: Product liability lawsuits.
  • Ongoing: Pricing pressures from governments and payers.

Growth Opportunities

  • Expansion of Skyrizi and Rinvoq: Skyrizi and Rinvoq are key growth drivers for AbbVie, with significant potential to expand their market share in the immunology space. The global market for psoriasis and rheumatoid arthritis treatments is estimated to reach $40 billion by 2028. AbbVie's focus on clinical trials and regulatory approvals for new indications will further fuel the growth of these products.
  • Oncology Pipeline Development: AbbVie is investing heavily in its oncology pipeline, with a focus on developing innovative therapies for various types of cancer. The global oncology market is projected to reach $300 billion by 2030. AbbVie's strategic collaborations and acquisitions in the oncology space will enhance its ability to compete in this rapidly growing market.
  • Neuroscience Portfolio Expansion: AbbVie is expanding its neuroscience portfolio, with a focus on developing treatments for neurological disorders such as Alzheimer's disease and Parkinson's disease. The global market for neuroscience therapeutics is estimated to reach $100 billion by 2027. AbbVie's research and development efforts in this area will drive future growth.
  • Eye Care Innovation: AbbVie is committed to innovation in eye care, with a focus on developing new treatments for glaucoma, dry eye disease, and other ophthalmic conditions. The global eye care market is projected to reach $50 billion by 2025. AbbVie's existing portfolio of eye care products, combined with its ongoing research and development efforts, will position it for continued success in this market.
  • Strategic Acquisitions and Partnerships: AbbVie continues to pursue strategic acquisitions and partnerships to expand its product portfolio and pipeline. These deals provide access to new technologies, therapeutic areas, and markets. AbbVie's disciplined approach to M&A ensures that it acquires assets that are aligned with its strategic priorities and have the potential to generate significant value.

Opportunities

  • Expansion of Skyrizi and Rinvoq.
  • Development of new therapies for unmet medical needs.
  • Strategic acquisitions and partnerships.
  • Growth in emerging markets.

Threats

  • Biosimilar competition for Humira.
  • Pricing pressures from governments and payers.
  • Regulatory challenges.
  • Product liability lawsuits.

Competitive Advantages

  • Strong patent protection for key products.
  • Extensive research and development capabilities.
  • Global sales and marketing network.
  • Established brand reputation.
  • Diversified product portfolio.

About ABBV

AbbVie Inc., established in 2012 as a spin-off from Abbott Laboratories, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines. Headquartered in North Chicago, Illinois, AbbVie has rapidly grown into a major player in the pharmaceutical industry, driven by its focus on addressing serious health issues across a range of therapeutic areas. The company's initial success was largely attributed to Humira, a blockbuster drug used to treat autoimmune diseases. While Humira remains a significant revenue contributor, AbbVie has strategically diversified its portfolio through internal research and development, as well as strategic acquisitions. Key products include Skyrizi for plaque psoriasis, Rinvoq for rheumatoid arthritis, Imbruvica and Venclexta for blood cancers, and Mavyret for hepatitis C. AbbVie also offers a range of other products, including Creon for pancreatic enzyme deficiency, Synthroid for hypothyroidism, Botox therapeutic, and various eye care solutions like Lumigan and Restasis. AbbVie's global reach extends to numerous countries, with a significant presence in the United States and Europe. The company continues to invest heavily in research and development to expand its pipeline and maintain a competitive edge in the rapidly evolving pharmaceutical landscape. AbbVie employs 55,000 people worldwide.

What They Do

  • Discovers and develops pharmaceutical products.
  • Manufactures pharmaceutical products.
  • Sells pharmaceutical products worldwide.
  • Focuses on therapies for autoimmune diseases.
  • Develops treatments for cancer.
  • Creates medications for neurological disorders.
  • Offers eye care solutions.

Business Model

  • Develops and patents pharmaceutical products.
  • Generates revenue through the sale of branded drugs.
  • Invests heavily in research and development to create new products.
  • Utilizes a global sales and marketing network to distribute products.

Industry Context

AbbVie operates in the highly competitive pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is driven by innovation, with companies constantly seeking to develop new and improved therapies. Key market trends include the increasing prevalence of chronic diseases, the growing demand for personalized medicine, and the rise of biosimilars. AbbVie competes with other major pharmaceutical companies, such as Amgen, AstraZeneca, Gilead, Johnson & Johnson, and Merck, all vying for market share in key therapeutic areas. The global pharmaceutical market is expected to continue growing, driven by an aging population and increasing healthcare spending.

Key Customers

  • Patients with autoimmune diseases.
  • Patients with cancer.
  • Patients with neurological disorders.
  • Healthcare providers.
  • Hospitals and clinics.
AI Confidence: 73% Updated: Feb 9, 2026

Financials

Chart & Info

AbbVie Inc. (ABBV) stock price: $205.06 (+0.13, +0.06%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABBV.

Price Targets

Consensus target: $254.22

MoonshotScore

52/100

What does this score mean?

The MoonshotScore rates ABBV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Drug Manufacturers - General

Competitors & Peers

Latest News

Latest AbbVie Inc. Analysis

What Investors Ask About AbbVie Inc. (ABBV)

What does AbbVie Inc. do?

AbbVie Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and sells a wide range of pharmaceutical products. Their primary focus is on developing therapies for serious health conditions in areas such as immunology, oncology, neuroscience, and eye care. Key products include Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta. AbbVie operates on a global scale, marketing its products to healthcare providers, hospitals, and patients worldwide. The company invests heavily in research and development to create innovative medicines and expand its product pipeline, aiming to address unmet medical needs and improve patient outcomes.

Is ABBV stock worth researching?

ABBV stock presents a mixed picture. The company faces challenges from biosimilar competition for Humira, a major revenue driver. However, the strong growth of Skyrizi and Rinvoq is expected to offset some of these declines. AbbVie's diversified product portfolio, robust pipeline, and commitment to R&D are positive factors. With a dividend yield of 2.98% and a beta of 0.33, ABBV offers a blend of income and relative stability. Investors should carefully consider the risks and opportunities before investing, focusing on the company's ability to successfully transition its revenue base and maintain profitability.

What are the main risks for ABBV?

AbbVie faces several key risks, primarily related to its reliance on Humira and the increasing competition from biosimilars. The erosion of Humira's market share could significantly impact revenue and profitability. Additionally, the company faces risks associated with the development and regulatory approval of new drugs, as well as potential product liability lawsuits. Pricing pressures from governments and payers also pose a threat to AbbVie's revenue. Successfully navigating these challenges will be crucial for AbbVie to maintain its competitive position and deliver long-term value to shareholders.

What are the key factors to evaluate for ABBV?

AbbVie Inc. (ABBV) currently holds an AI score of 52/100, indicating moderate score. The stock trades at a P/E of 12.7x, below the S&P 500 average (~20-25x), potentially signaling value. Analysts target $254.22 (+24% from $205.06). Key strength: Diversified product portfolio.. Primary risk to monitor: Ongoing: Biosimilar competition for Humira impacting revenue.. This is not financial advice.

How frequently does ABBV data refresh on this page?

ABBV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ABBV's recent stock price performance?

Recent price movement in AbbVie Inc. (ABBV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $254.22 implies 24% upside from here. Notable catalyst: Diversified product portfolio.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ABBV overvalued or undervalued right now?

Determining whether AbbVie Inc. (ABBV) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 12.7. Analysts target $254.22 (+24% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ABBV?

Before investing in AbbVie Inc. (ABBV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment decisions should be made based on individual risk tolerance and financial circumstances.
Data Sources

Popular Stocks